Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (Abstract 5).
Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implications for survival, and the link to a deficiency in mismatched repair genes (Abstract 9).
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—including a subset of pancreatic cancers, which appear to be highly immunogenic and are associated with long-term survival.
Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients with a good performance status (Abstract 208).
Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer (Abstract 1).
